Phase II Study of bi-weekly SOX+Cetuximab for EGFR positive and K-ras wild type dvanced and recurrent Colorectal Cancer

ABSTRACT: Interventions: Oxaliplatin:85mg/m2/week iv, day1.15 q 4weeks Cetuximab:day1 400, day8 250, day15 500mg/m2, day15- q 2weeks S-1:80mg/m2, day1-14 q 4weeks Primary outcome(s): Response ratte : RR Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2621320 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR